ArticleGastro hep advances2026
Baveno Criteria Spare Endoscopies Among Patients With Compensated Cirrhosis Within a Large US Healthcare System.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The Baveno criteria have been validated in populations outside of the United States and have been shown to accurately rule out clinically significant portal hypertension (CSPH) and high-risk varices. The criteria have been adopted by European and US guidelines. We aim to evaluate the performance characteristics of the Baveno VI criteria in a large US healthcare system. Methods: Patients evaluated within Kaiser Permanente Northern California with cirrhosis (liver stiffness measurement ≥10 kPa) who underwent a FibroScan between 2016 and 2022 and an upper endoscopy within 12 months were included. Endoscopic and imaging findings were assessed. We evaluated the performance characteristics of the Baveno VI criteria for ruling out CSPH based on endoscopic and radiologic evidence consistent with CSPH. Results: Among 428 patients, the sensitivity of the Baveno VI criteria for ruling out CSPH was determined to be 84.8%. The sensitivity for identifying medium/large varices was 95.1%. Applying Baveno criteria would spare 90 endoscopies. Conclusion: Application of the Baveno criteria spares 21% of unnecessary endoscopies with a low risk of missing high-risk varices, confirming that the Baveno criteria can be confidently adopted in the United States to rule out CSPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.